# Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan

> **NCT03208543** · PHASE3 · TERMINATED · sponsor: **Medecins Sans Frontieres, Netherlands** · enrollment: 56 (actual)

## Conditions studied

- Cutaneous Leishmaniases

## Interventions

- **DEVICE:** HECT-CL

## Key facts

- **NCT ID:** NCT03208543
- **Lead sponsor:** Medecins Sans Frontieres, Netherlands
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-04
- **Primary completion:** 2017-12-20
- **Final completion:** 2017-12-20
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** failure rate 91.1%
- **Last updated:** 2019-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03208543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03208543, "Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03208543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*